• AstraZeneca Says Dato-DXd Meets Dual Primary Endpoint Of PFS In Phase III Trial In Lung Cancer

    来源: NASDAQ US Markets / 03 7月 2023 01:35:15   America/Chicago

    (RTTNews) - British drug major AstraZeneca plc (AZN, AZN.L) announced Monday positive high-level results from the TROPION-Lung01 Phase III trial of datopotamab deruxtecan (Dato-DXd) in patients with advanced non-small cell lung cancer. https://www.nasdaq.com/articles/astrazeneca-says-dato-dxd-meets-dual-primary-endpoint-of-pfs-in-phase-iii-trial-in-lung
分享